Phenylephrine

also known as Phenylephrine Hydrochloride · Phenylephrine HCl · Mydfrin · BAY112476 · Biorphen · PE HCl · PEH · PHE · +6 more

Small molecule

Developed for: hypotensive disorder · hypertensive disorder · cataract · infectious disease with sepsis · seasonal allergic rhinitis · common cold · ischemic stroke · respiratory tract infectious disorder
+24 more
· rhinitis · acute kidney injury · allergic rhinitis · arterial disorder · brain hypoxia - ischemia · preeclampsia · syncope, familial vasovagal · Achoo syndrome · baldness, male pattern · bronchiolitis · heart failure · influenza · intraoperative floppy iris syndrome · mouth disorder · nasal cavity disorder · pulmonary arterial hypertension · telogen effluvium · vasomotor rhinitis · acute myocardial infarction · chemotherapy-induced alopecia · eye disorder · hemorrhoid · mucositis · traumatic brain injury
Investigated by: General Hospital of Ningxia Medical University · Bayer · Eyenovia Inc. · IWK Health Centre · Omeros Corporation · University of Alberta
+121 more
· Ache Laboratorios Farmaceuticos S.A. · GlaxoSmithKline · KK Women's and Children's Hospital · Seoul National University Hospital · University of Wisconsin, Madison · Aristotle University Of Thessaloniki · Beijing Tiantan Hospital · Cairo University · Inje University · Johns Hopkins University · Khon Kaen University · Mayo Clinic · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH) · Samsung Medical Center · Samuel Lunenfeld Research Institute, Mount Sinai Hospital · The Second Affiliated Hospital of Dalian Medical University · University Hospital, Ghent · University of California, San Francisco · University of Michigan · University of Roma La Sapienza · Wake Forest University Health Sciences · Xuzhou Medical University · Aarhus University Hospital · Akron Children's Hospital · Algemeen Ziekenhuis Maria Middelares · American University of Beirut Medical Center · Applied Biology, Inc. · AstraZeneca · Baylor College of Medicine · Burapha University · Cambridge University Hospitals NHS Foundation Trust · Canadian Critical Care Trials Group · Canadian Institutes of Health Research (CIHR) · Carilion Clinic · Central Hospital, Nancy, France · China International Neuroscience Institution · Colorado State University · Crystal A. Gadegbeku · DHS Consulting · Dalian Municipal Central Hospital · Daniel Alain, Inc. · Dar El Oyoun Hospital · Denver Health and Hospital Authority · Duke University · Eurofarma Laboratorios S.A. · Follea International Limited · Fonds de la Recherche en Santé du Québec · Francois Lamontagne · Georgetown University · Gyeongsang National University Hospital · Jason Chui · Johnson & Johnson Consumer and Personal Products Worldwide · KIST Medical and Teaching Hospital · Keimyung University Dongsan Medical Center · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Medical University of Vienna · Montefiore Medical Center · Murdoch University · NYU Langone Health · National Center for Research Resources (NCRR) · National Heart, Lung, and Blood Institute (NHLBI) · National and Kapodistrian University of Athens · Nepal Health Research Council · New York Medical College · New York Presbyterian Brooklyn Methodist Hospital · Northwestern University · Novartis · Organon and Co · Oslo University Hospital · Peking University First Hospital · Peking University People's Hospital · Pfizer · Pontificia Universidad Catolica de Chile · all 127 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	BIORPHEN	—	2021-03-11	fda.gov ↗
Approved	EU (EMA)	Omidria	—	2015-07-28	europa.eu ↗
Approved	US (FDA)	PHENERGAN W/ CODEINE	—	1952-01-21	fda.gov ↗

Trials 147 · started per year

today

US approved 1952

EU approved 2015

19501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 08 trials
Phase 0	NCT06539637	Sep 2023 → Nov 2025 overdue	cataract	DHS Consulting	Recruiting	No outcome recorded
Phase 0	NCT06288321	Aug 2022 → Mar 2023	retinopathy of prematurity	The University of Hong Kong	Completed	No outcome recorded
Phase 0	NCT05011357	Sep 2021 → Aug 2024	—	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 0	NCT04436731	Dec 2020 → Jun 2026 overdue	obesity disorder	University of Missouri-Columbia	Active not recruiting	No outcome recorded
Phase 0	NCT04218773	Sep 2020 → Aug 2026	hypertensive disorder, ischemic stroke	Yale University	Suspended	No outcome recorded Stop: Business
Phase 0	NCT03972683	Apr 2019 → Jul 2021	—	Colorado State University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 0	NCT03719001	Oct 2018 → Jun 2022	vascular disorder	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT01791816	Feb 2013 → Dec 2022	postural orthostatic tachycardia syndrome, syncope, familial vasovagal	New York Medical College	Completed	No outcome recorded
Phase 16 trials
Phase 1	NCT03415243	Mar 2018	common cold	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03098680	Apr 2017 → Feb 2020	cardiovascular disorder	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01731444	Dec 2014 → Jun 2028 expected	—	University of Manitoba	Recruiting	No outcome recorded
Phase 1	NCT02009007	Dec 2012 → Jun 2014	brain hypoxia - ischemia, hypotensive disorder	Samsung Medical Center	Unknown	No outcome recorded
Phase 1	NCT01092975	Mar → Nov 2010	stomatitis	University of Wisconsin, Madison	Terminated	No outcome recorded
Phase 1	NCT00762567	Sep → Nov 2008	rhinitis	Johnson & Johnson Consumer and Personal Products Worldwide	Completed	No outcome recorded
Phase 1/24 trials
Phase 1/2	NCT07075224	Nov 2025	—	Unither Pharmaceuticals, France	Completed	No outcome recorded
Phase 1/2	NCT04500899	Dec 2020 → Jun 2026 overdue	mitral valve insufficiency	Montefiore Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT02434146	May 2015 → Apr 2016	disease related to transplantation, mouth disorder, neoplasm	University of Wisconsin, Madison	Terminated	No outcome recorded
Phase 1/2	NCT00972998	Sep → Dec 2009	—	RDD Pharma Ltd	Completed	No outcome recorded
Phase 210 trials · 2 missed
Phase 2	NCT04972123	Jul 2021 → Aug 2023	syncope, familial vasovagal	University of Wisconsin, Madison	Completed	Missed primary
Phase 2	NCT04089072	Dec 2019 → Oct 2024	infectious disease with sepsis	Carilion Clinic	Unknown	No outcome recorded
Phase 2	NCT02946125	Oct → Nov 2016	—	Eyenovia Inc.	Completed	No outcome recorded
Phase 2	NCT01533662	Mar 2011 → May 2013	—	University Hospital, Toulouse	Completed	No outcome recorded
Phase 2	NCT01330017	Mar → May 2011	seasonal allergic rhinitis	Bayer	Completed	Missed primary
Phase 2	NCT00639015	Nov 2007 → Jun 2008	infectious disease with sepsis	University of Roma La Sapienza	Completed	No outcome recorded
Phase 2	NCT00481442	Jan → Mar 2007	infectious disease with sepsis	University of Roma La Sapienza	Completed	No outcome recorded
Phase 2	NCT00373802	Jan → Jun 2005	bronchiolitis	Akron Children's Hospital	Completed	No outcome recorded
Phase 2	NCT00227448	Jun 2003 → Apr 2005	ischemic stroke	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT00431392	Sep 2001 → ?	—	Medical University of Vienna	Completed	No outcome recorded
Phase 2/34 trials · 1 met primary
Phase 2/3	NCT06648850	May 2026 → Mar 2027 expected	baldness, male pattern, telogen effluvium	Applied Biology, Inc.	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03833895	Feb → Sep 2019	—	China International Neuroscience Institution	Completed	No outcome recorded
Phase 2/3	NCT02277730	May 2013 → Nov 2017	hypotensive disorder	KK Women's and Children's Hospital	Completed	Met primary
Phase 2/3	NCT04025918	Oct 2011 → Jul 2012	hypotensive disorder	KK Women's and Children's Hospital	Completed	No outcome recorded
Phase 323 trials · 2 met primary · 3 missed
Phase 3	NCT05118672	Mar → Aug 2025	influenza	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT05070650	Sep 2024 → Apr 2025	common cold	Sandoz	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT05706727	Mar 2023 → Apr 2024	—	KIST Medical and Teaching Hospital	Completed	No outcome recorded
Phase 3	NCT02904304	Dec 2020 → Jul 2021	—	Ache Laboratorios Farmaceuticos S.A.	Suspended	No outcome recorded
Phase 3	NCT04067817	Oct → Dec 2019	hypotensive disorder	The Second Affiliated Hospital of Dalian Medical University	Unknown	No outcome recorded
Phase 3	NCT03751631	Nov 2018 → Jan 2019	—	Eyenovia Inc.	Completed	No outcome recorded
Phase 3	NCT02678234	Feb → Apr 2017	respiratory tract infectious disorder	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT02730364	Feb → Apr 2017	respiratory tract infectious disorder	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT03215797	Sep → Dec 2016	hypotensive disorder	The Second Affiliated Hospital of Dalian Medical University	Completed	No outcome recorded
Phase 3	NCT01938144	Apr → Nov 2016	common cold	Pfizer	Withdrawn	No outcome recorded
Phase 3	NCT02401191	Mar → Jul 2015	allergic rhinitis	Sanofi	Completed	No outcome recorded
Phase 3	NCT01393548	Aug 2014 → Nov 2016	rhinitis	Ache Laboratorios Farmaceuticos S.A.	Completed	No outcome recorded
Phase 3	NCT01393561	Jul → Oct 2014	rhinitis	Ache Laboratorios Farmaceuticos S.A.	Completed	No outcome recorded
Phase 3	NCT02093689	Feb → Aug 2014	intraoperative floppy iris syndrome	Omeros Corporation	Terminated	No outcome recorded
Phase 3	NCT01448057	Jul 2013 → Aug 2015	Achoo syndrome, nasal cavity disorder, respiratory tract infectious disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT01600235	Jun 2012 → Dec 2017	ischemic stroke	Samsung Medical Center	Unknown	Met primary
Phase 3	NCT04534452	May → Jun 2012	allergic rhinitis	Bayer	Completed	No outcome recorded
Phase 3	NCT01579565	Apr → Nov 2012	—	Omeros Corporation	Completed	Met primary
Phase 3	NCT01413958	Aug → Oct 2011	seasonal allergic rhinitis	Bayer	Completed	Missed primary
Phase 3	NCT00976209	Aug → Nov 2009	seasonal allergic rhinitis, vasomotor rhinitis	Bayer	Completed	No outcome recorded
Phase 3	NCT00874120	Dec 2008 → Feb 2009	hypertensive disorder	Bayer	Completed	Missed primary
Phase 3	NCT00420797	Feb → Nov 2007	—	S.L.A. Pharma AG	Withdrawn	No outcome recorded
Phase 3	NCT00276016	Jan → Feb 2006	seasonal allergic rhinitis	Organon and Co	Completed	Missed primary

Phase 444 trials · 5 met primary · 1 missed
Phase 4	NCT07824713	Sep 2026 → Jan 2027 expected	—	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07662408	May 2026 → Mar 2027 expected	—	Sohag University	Recruiting	No outcome recorded
Phase 4	NCT06366217	Oct 2024 → Jul 2025	abnormal pupillary function	University of California, San Francisco	Completed	Met primary
Phase 4	NCT07327320	Jun 2024 → Oct 2025	hypotensive disorder	Tam Anh Research Institute	Completed	No outcome recorded
Phase 4	NCT05890027	Mar 2024 → Apr 2025	ptosis	University of Miami	Completed	No outcome recorded
Phase 4	NCT06334549	Mar 2024 → Dec 2025 overdue	hypotensive disorder	Dalian Municipal Central Hospital	Recruiting	No outcome recorded
Phase 4	NCT06217796	Nov 2023 → Jan 2024	—	Eyenovia Inc.	Completed	No outcome recorded
Phase 4	NCT05997732	Oct 2023 → Dec 2027 expected	—	University of Alberta	Recruiting	No outcome recorded
Phase 4	NCT05941494	Oct 2023 → Dec 2025	—	Jason Chui	Unknown	No outcome recorded
Phase 4	NCT04829799	Feb 2022 → Aug 2023	—	University of Florida	Withdrawn	No outcome recorded
Phase 4	NCT04991662	Oct → Dec 2021	—	Xuzhou Medical University	Completed	No outcome recorded
Phase 4	NCT05043077	Sep 2021 → Jan 2023	retinopathy of prematurity	Aristotle University Of Thessaloniki	Completed	Met primary
Phase 4	NCT04907474	May → Jun 2021	—	Eyenovia Inc.	Completed	Met primary
Phase 4	NCT04602767	Oct 2020 → May 2024	acute kidney injury	Thomas Jefferson University	Unknown	No outcome recorded
Phase 4	NCT04419662	May 2020 → May 2021	—	Aarhus University Hospital	Completed	No outcome recorded
Phase 4	NCT04623684	Mar → Sep 2020	retinopathy of prematurity	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT03864133	Jul 2019 → Jun 2021	cataract	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT03846765	Jul 2019 → May 2021	—	University Hospital, Ghent	Completed	No outcome recorded
Phase 4	NCT03638726	Sep 2018 → Mar 2019	cataract	Dar El Oyoun Hospital	Unknown	No outcome recorded
Phase 4	NCT03615508	Sep 2018 → May 2019	Horner syndrome	Denver Health and Hospital Authority	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03302039	Oct 2017 → Oct 2018	—	Cairo University	Completed	No outcome recorded
Phase 4	NCT03248817	Sep 2017 → May 2020	—	Cairo University	Unknown	No outcome recorded
Phase 4	NCT03767296	Feb → Sep 2017	—	University Hospital, Ghent	Completed	No outcome recorded
Phase 4	NCT02979405	Jan → Feb 2017	hypotensive disorder	Universidad Industrial de Santander	Completed	No outcome recorded
Phase 4	NCT02748265	Mar 2016 → Jul 2017	—	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT02739399	Feb → Jul 2016	hypotensive disorder	Algemeen Ziekenhuis Maria Middelares	Completed	No outcome recorded
Phase 4	NCT02802683	Sep 2015 → May 2016	hypotensive disorder	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT02665221	Jul 2015 → Sep 2016	multiple sclerosis	NYU Langone Health	Terminated	No outcome recorded
Phase 4	NCT02323399	Feb 2015 → Dec 2024 overdue	hypotensive disorder	West-Ward Pharmaceutical	Recruiting	No outcome recorded
Phase 4	NCT02354833	Aug 2014 → Aug 2015	—	West Virginia University	Completed	Missed primary
Phase 4	NCT02177539	May → Aug 2014	refractive error	Pontificia Universidad Catolica de Chile	Unknown	No outcome recorded
Phase 4	NCT02376192	Jan → Dec 2014	pregnancy disorder	IWK Health Centre	Completed	No outcome recorded
Phase 4	NCT01378325	Jul 2012 → Jan 2013	—	American University of Beirut Medical Center	Completed	No outcome recorded
Phase 4	NCT01794273	Jul 2012 → Jul 2013	—	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 4	NCT05439460	Jan 2012 → Jun 2014	pulmonary arterial hypertension	Stanford University	Completed	No outcome recorded
Phase 4	NCT04838665	Sep 2011	retinopathy of prematurity	University of the Philippines	Completed	No outcome recorded
Phase 4	NCT01481740	Nov 2010 → Dec 2014	hypotensive disorder	IWK Health Centre	Completed	Met primary
Phase 4	NCT00877175	Mar → May 2009	—	Khon Kaen University	Completed	Met primary
Phase 4	NCT00846690	Jan → Mar 2009	—	The University of Texas Health Science Center, Houston	Unknown	No outcome recorded
Phase 4	NCT00796328	Nov 2008 → Feb 2009	—	IWK Health Centre	Terminated	No outcome recorded
Phase 4	NCT02885168	Feb 2008 → Apr 2009	infectious disease with sepsis	Central Hospital, Nancy, France	Completed	No outcome recorded
Phase 4	NCT00781157	Jan → Aug 2008	hypotensive disorder	IWK Health Centre	Completed	No outcome recorded
Phase 4	NCT00501878	May → Jul 2007	diabetes mellitus	Khon Kaen University	Completed	No outcome recorded
Phase 4	NCT00199784	Jun 2005 → Apr 2007	—	Oslo University Hospital	Completed	No outcome recorded

Phase not applicable48 trials · 1 met primary · 4 missed
—	NCT07663149	Apr → Jun 2026	—	Universitas Indonesia	Completed	No outcome recorded
—	NCT06508359	Aug 2025 → Apr 2026	—	General Hospital of Ningxia Medical University	Completed	No outcome recorded
—	NCT06158035	Jul → Dec 2025	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
—	NCT06151470	Jul → Dec 2025	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
—	NCT06158009	Apr → Jun 2025	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
—	NCT06151522	Apr → Jun 2025	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
—	NCT06914063	Mar → Jun 2025 overdue	cycloplegia	Superior University	Active not recruiting	No outcome recorded
—	NCT07153601	Feb → May 2025	hypotensive disorder, pregnancy disorder	Universitas Sumatera Utara	Completed	No outcome recorded
—	NCT06158048	Jan → Apr 2025	—	General Hospital of Ningxia Medical University	Completed	No outcome recorded
—	NCT07495670	Nov 2024 → Jan 2025	diabetes mellitus, diabetic retinopathy	Burapha University	Completed	No outcome recorded
—	NCT06158022	Oct 2024 → May 2025	—	General Hospital of Ningxia Medical University	Completed	No outcome recorded
—	NCT06711432	Sep 2024 → May 2026 overdue	neoplasm, stroke disorder	Zhejiang Cancer Hospital	Recruiting	No outcome recorded
—	NCT04576663	Oct 2023 → Sep 2025	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
—	NCT05414877	Sep 2023 → Dec 2024	arterial disorder	Beijing Tiantan Hospital	Unknown	No outcome recorded
—	NCT05665881	Jan 2023 → Sep 2024	arterial disorder	Beijing Tiantan Hospital	Completed	No outcome recorded
—	NCT05525416	Jul 2022 → Feb 2023	—	University of Alberta	Completed	No outcome recorded
—	NCT04928183	Jun → Aug 2021	isoproterenol-mediated vasodilatation	University of Alberta	Completed	No outcome recorded
—	NCT04214145	Jan 2020 → Sep 2021	—	Seoul National University Hospital	Completed	No outcome recorded
—	NCT05001048	Aug 2019 → Dec 2021	isoproterenol-mediated vasodilatation	University of Alberta	Completed	No outcome recorded
—	NCT04053478	Jul 2019 → Dec 2026 expected	hypotensive disorder	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Recruiting	No outcome recorded
—	NCT04133961	Jun → Dec 2019	—	Universiti Kebangsaan Malaysia Medical Centre	Completed	No outcome recorded
—	NCT04777383	Apr 2019 → Oct 2021	vascular disorder	University Hospital, Linkoeping	Terminated	No outcome recorded
—	NCT03620942	Nov 2018 → Dec 2025 overdue	hypotensive disorder	KK Women's and Children's Hospital	Active not recruiting	Missed primary
—	NCT03682198	Sep 2018 → Oct 2020	—	University Hospital Bispebjerg and Frederiksberg	Completed	No outcome recorded
—	NCT03629418	Aug 2018 → Dec 2025 overdue	acute kidney injury	Peking University First Hospital	Recruiting	No outcome recorded
—	NCT03507387	Apr → Aug 2018	—	Xuzhou Medical University	Completed	No outcome recorded
—	NCT02965924	Oct 2016 → Oct 2018	—	Mayo Clinic	Completed	No outcome recorded
—	NCT02909140	Sep 2016 → Aug 2018	cataract	Johns Hopkins University	Terminated	No outcome recorded Stop: Enrollment
—	NCT02725060	Feb 2016 → Oct 2026 expected	cardiac rhythm disease, postural orthostatic tachycardia syndrome, primary dysautonomia	Vanderbilt University Medical Center	Enrolling by invitation	No outcome recorded
—	NCT02585570	Oct 2015 → Sep 2016	—	Inje University	Completed	No outcome recorded
—	NCT02101047	Aug 2015 → Dec 2016	—	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
—	NCT02382185	Jan 2015 → Sep 2017	—	York Teaching Hospitals NHS Foundation Trust	Completed	Missed primary
—	NCT02285634	Nov 2014 → Dec 2016	hypertensive disorder	Mayo Clinic	Completed	Missed primary
—	NCT02245191	Jul 2014	preeclampsia	University of Sao Paulo General Hospital	Unknown	No outcome recorded
—	NCT01866657	Jun 2013 → Nov 2016	brain hypoxia - ischemia	University Hospitals Cleveland Medical Center	Terminated	No outcome recorded Stop: Business
—	NCT01800877	Apr 2013 → Dec 2014	hypotensive disorder	Francois Lamontagne	Completed	No outcome recorded
—	NCT01813149	Aug 2012 → Jun 2016	complex regional pain syndrome	The Cleveland Clinic	Terminated	Met primary
—	NCT01080625	Apr 2010 → Sep 2011	—	Seoul National University Hospital	Completed	No outcome recorded
—	NCT00838695	Jan 2009 → Dec 2010	—	Vanderbilt University	Completed	No outcome recorded
—	NCT01054027	Mar → Nov 2007	retinopathy of prematurity	Georgetown University	Completed	No outcome recorded
—	NCT00379691	Aug → Dec 2006	hypotensive disorder	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Completed	No outcome recorded
—	NCT00356265	Jul 2006 → Nov 2010	chronic kidney disease, hypertensive disorder	University of Michigan	Terminated	No outcome recorded Stop: Enrollment
—	NCT00458003	Jul 2006 → Dec 2016	hypotensive disorder, preeclampsia	Northwestern University	Completed	Missed primary
—	NCT00294606	Feb 2006	—	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
—	NCT00240058	Jul 2005 → Jun 2006	hypertensive disorder	Crystal A. Gadegbeku	Completed	No outcome recorded
—	NCT00225043	Jun 2005 → Aug 2007	—	New York Presbyterian Brooklyn Methodist Hospital	Completed	No outcome recorded
—	NCT00585091	Oct 2003 → Aug 2007	heart failure	University of Utah	Completed	No outcome recorded
—	NCT00100412	Oct 1999 → Sep 2002	myalgic encephalomeyelitis/chronic fatigue syndrome, persian gulf syndrome, post-traumatic stress disorder	US Department of Veterans Affairs	Completed	No outcome recorded

Comparator or background therapy109 trials
Phase 0	NCT06053398 Comparator	Nov 2023 → Dec 2024	hypotensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 0	NCT02759510 Comparator	Jun 2016	heart failure	RenJi Hospital	Unknown	No outcome recorded
Phase 1	NCT03680404 Comparator	Oct 2018 → Feb 2020	vascular disorder	The University of Texas at Arlington	Completed	No outcome recorded
Phase 1	NCT03139708 Background	Sep 2016 → Oct 2017	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT02245230 Background	Jan 2015 → Dec 2023	essential hypertension	Vanderbilt University	Terminated	No outcome recorded Stop: Enrollment
Show all 109 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 8

Date	Issuer	Release
2019-11-04	Omeros Corporation	Results Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain omeros.com ↗ Patients in the OMIDRIA group were 6.7 times more likely not to require fentanyl, with 9.8 percent of OMIDRIA patients requiring fentanyl versus 42.1 percent of epinephrine patients (P = 0.006).
2019-05-07	Omeros Corporation	Results Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting omeros.com ↗ Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids
2018-10-01	Omeros Corporation	Regulatory Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® omeros.com ↗ CMS’ Separate Payment for Cataract Surgery Drug Resumes Today
2018-04-19	Omeros Corporation	Results Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting omeros.com ↗ Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C. , April 13-17, 2018 .
2017-12-12	Omeros Corporation	Regulatory Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients omeros.com ↗ FDA approved the sNDA for OMIDRIA under priority review.
2016-11-21	Omeros Corporation	Results Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial omeros.com ↗ In the trial, OMIDRIA was safe and well tolerated with adverse event rates consistent with those seen in pediatric cataract surgery and similar in the OMIDRIA and phenylephrine groups.
2016-01-15	Omeros Corporation	Results Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference omeros.com ↗ the use of Omidria across a wide range of patients, including those with non-complex cataracts, complex cataracts, intraoperative floppy iris syndrome (IFIS) and/or pseudoexfoliation, has resulted in statistically significant:
2014-07-08	Perrigo Company	Regulatory Perrigo Announces FDA Final Approval For The Store Brand Equivalent To Advil® Congestion Relief Tablets, 200 mg/10 mg perrigo.com ↗ This approval further strengthens our leading store brand position and highlights our commitment to bringing new affordable products to the market.

All press releases naming this drug 21 releases

Date	Issuer	Release
2026-03-23	Novartis Pharmaceuticals	Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 novartis.com ↗
2025-12-30	Roxane Laboratories	Delivering emergency relief through our partnership with Direct Relief hikma.com ↗
2023-12-19	Roxane Laboratories	Hikma launches Phenylephrine HCl Injection, USP, in ready-to-use vials in the US hikma.com ↗
2023-07-21	Pfizer	Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility pfizer.com ↗
2020-06-17	Bayer	Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19 bayer.com ↗
2020-06-04	Novartis Pharmaceuticals	Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis novartis.com ↗
2019-11-12	Novartis Pharmaceuticals	New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis novartis.com ↗
2019-11-04	Omeros Corporation	Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain omeros.com ↗
2019-05-07	Omeros Corporation	Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting omeros.com ↗
2019-03-05	Janssen Research & Development, LLC	Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief jnj.com ↗
2018-10-01	Omeros Corporation	Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® omeros.com ↗
2018-04-19	Omeros Corporation	Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting omeros.com ↗
2017-12-12	Omeros Corporation	Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients omeros.com ↗
2016-11-21	Omeros Corporation	Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial omeros.com ↗
2016-01-15	Omeros Corporation	Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference omeros.com ↗
2015-12-15	GlaxoSmithKline	Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems gsk.com ↗
2015-02-02	Novartis Pharmaceuticals	Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief novartis.com ↗
2014-09-04	Janssen Research & Development, LLC	Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid jnj.com ↗
2014-07-24	GlaxoSmithKline	FDA approves Flonase allergy relief for sale over-the-counter in the United States gsk.com ↗
2014-07-08	Perrigo Company	Perrigo Announces FDA Final Approval For The Store Brand Equivalent To Advil® Congestion Relief Tablets, 200 mg/10 mg perrigo.com ↗
2010-01-17	GlaxoSmithKline	GSK contributes to Haiti relief efforts gsk.com ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 258 sources stand behind the page.

Field	Value	Cited text
Known as	phenylephrine	“The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗ 245 “Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium...” NCT01579565 ↗ “Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium...” NCT02093689 ↗ “A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more effective than placebo in the symptomatic treatment of the common cold or flu-like...” PMID 24261438 ↗ Nov 2013 “Protocol-directed vasopressor administration based on hemodynamic monitoring data. Agents included norepinephrine, phenylephrine, epinephrine, dopamine, and vasopressin.” NCT02742974 ↗ “standard Mydrin-P (0.5% tropicamide / 0.5% phenylephrine HCl) which is the standard eyedrops used for dilation of pupil before retinopathy of prematurity examination.” NCT06288321 ↗ “Rapid-Onset Cycloplegic Drops (e.g., tropicamide with phenylephrine) to assess patient comfort, anxiety, and satisfaction with quicker onset and shorter duration.” NCT06914063 ↗ “a combination topical anesthetic, consisting of 20% lidocaine, 4% tetracaine and 2% phenylephrine (TAC Alternate Gel, Compounding Arts Pharmacy, Lafayette, LA).” NCT00846690 ↗ “The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine.” NCT02735070 ↗ “Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value” NCT02382185 ↗ “Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine.” NCT00940836 ↗ Show 235 more sources
Known as	BAY112476	“Phenylephrine HCl (Sinus Comfort, BAY112476)” NCT04534452 ↗
Known as	Biorphen	“phenylephrine {Generic Name: Biorphen}” NCT06539637 ↗
Known as	Mydfrin	“Multiple Alternate Instillation of Cyclopentolate Hydrochloride Dilate® Micro Labs Limited Bangalore and Phenylephrine Hydrochloride Mydfrin™ 25mg/mL (2.5%) Alcon Fort Worth Texas” NCT04838665 ↗ 1 NCT04500899 ↗
Known as	PE HCl	“Phenylephrine hydrochloride (PE HCl) is widely used” PMID 26143019 ↗ Jul 2015
Known as	PEH	“Over-the-counter phenylephrine hydrochloride (PEH) is used for relief of nasal congestion caused by allergic rhinitis; however, data to support its efficacy are lacking.” PMID 26560899 ↗ Nov 2015
Known as	PHE	“the same infusion modalities of phenylephrine (PHE) with more stable blood pressure and less bradycardia” NCT06248593 ↗
Known as	Phenylenphrine	“Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg” NCT04214145 ↗
Known as	Phenylephrin	“eye drops (Phenylephrin)” NCT04880928 ↗
Known as	Phenylephrine HCl	“Phenylephrine HCL is considered to be the vasopressor of choice in parturients due to its propensity to cause less fetal acidosis.” NCT05348980 ↗ 5 “Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.” NCT00874120 ↗ “Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.” NCT00976209 ↗ “Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis” PMID 26143019 ↗ Jul 2015 NCT04534452 ↗ NCT02730364 ↗
Known as	Phenylephrine Hydrochloride	“The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗ 15 “Multiple Alternate Instillation of Cyclopentolate Hydrochloride Dilate® Micro Labs Limited Bangalore and Phenylephrine Hydrochloride Mydfrin™ 25mg/mL (2.5%) Alcon Fort Worth Texas” NCT04838665 ↗ “Over-the-counter phenylephrine hydrochloride (PEH) is used for relief of nasal congestion caused by allergic rhinitis; however, data to support its efficacy are lacking.” PMID 26560899 ↗ Nov 2015 “Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg).” NCT01048125 ↗ “Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery” NCT02946125 ↗ “Phenylephrine Hydrochloride (Phenylephrine HCl) extended release tablet” NCT04534452 ↗ “RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed” NCT05157711 ↗ “Phenylephrine hydrochloride (PE HCl) is widely used” PMID 26143019 ↗ Jul 2015 “Drug: Phenylephrine hydrochloride infusion” NCT07824713 ↗ “10% Phenylephrine hydrochloride gel” NCT00420797 ↗ “Drug: Phenylephrine Hydrochloride” NCT05525416 ↗ Show 5 more sources
Known as	Preparation H	“Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.” NCT02665221 ↗
Known as	RELIEF	“RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed” NCT05157711 ↗
Known as	RELIEF rectal ointment (phenylephrine hydrochloride)	“RELIEF rectal ointment (phenylephrine hydrochloride)” NCT05157711 ↗
Known as	Sinus Comfort	“Phenylephrine HCl (Sinus Comfort, BAY112476)” NCT04534452 ↗
Action	Activate	“Phenylephrine is an alpha-adrenergic agonist that increases blood pressure by constricting peripheral blood vessels.” NCT00100412 ↗
Modality	Small molecule	“Phenylephrine and dobutamine are synthetic catecholamines, analogues of endogenous chemical messenger substances released by sympathetic nerve fibers and by adrenal medulla...” NCT00100412 ↗
Route	Intravenous	“The hypotheses of target organ dysfunction are evaluated using graded intravenous infusions of two drugs, phenylephrine and dobutamine, and by measuring the resultant...” NCT00100412 ↗